1. Home
  2. ACRS vs STRO Comparison

ACRS vs STRO Comparison

Compare ACRS & STRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Aclaris Therapeutics Inc.

ACRS

Aclaris Therapeutics Inc.

HOLD

Current Price

$4.85

Market Cap

311.0M

Sector

Health Care

ML Signal

HOLD

Logo Sutro Biopharma Inc.

STRO

Sutro Biopharma Inc.

HOLD

Current Price

$40.61

Market Cap

338.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ACRS
STRO
Founded
2012
2003
Country
United States
United States
Employees
N/A
131
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
311.0M
338.9M
IPO Year
2015
N/A

Fundamental Metrics

Financial Performance
Metric
ACRS
STRO
Price
$4.85
$40.61
Analyst Decision
Strong Buy
Buy
Analyst Count
5
9
Target Price
$10.20
$31.33
AVG Volume (30 Days)
1.3M
248.1K
Earning Date
05-07-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
69.01
N/A
EPS
N/A
N/A
Revenue
$1,683,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$4.24
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.22
$0.67
52 Week High
$4.94
$41.88

Technical Indicators

Market Signals
Indicator
ACRS
STRO
Relative Strength Index (RSI) 64.65 71.40
Support Level $2.67 $0.78
Resistance Level $4.89 N/A
Average True Range (ATR) 0.27 2.96
MACD 0.03 0.20
Stochastic Oscillator 72.12 78.48

Price Performance

Historical Comparison
ACRS
STRO

About ACRS Aclaris Therapeutics Inc.

Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.

About STRO Sutro Biopharma Inc.

Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. The company also pipeline contains STRO-004, STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.

Share on Social Networks: